Stock RGLS REGULUS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
2.02 USD +5.21% Intraday chart for Regulus Therapeutics Inc. +1.00% +57.81%
May. 16 Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer CI
May. 09 Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
APPENDIX A REGULUS THERAPEUTICS INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 15, 2019 APPROVED BY THE STOCKHOLDERS: AUGUST 1, 2019 AMENDED BY THE BOARD OF DIRECTORS: APRIL 20, 2023 APPROVED BY THE STOCKHOLDERS: JUNE 13, 2023 AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2024 APPROVED BY THE STOCKHOLDERS: MAY 16, 2024 - Form 8-K
PU
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
PR
Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer
CI
Regulus: Q1 Earnings Snapshot
AQ
Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
PR
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
PR
Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Regulus: Q4 Earnings Snapshot
AQ
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
PR
Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating
MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target
MT
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
AQ
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors
CI
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating
MT
Top Midday Gainers
MT
Regulus Therapeutics Reports 'Positive' Data From Second Cohort of Kidney Disease Trial -- Shares Rise
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGLS Stock
  4. News Regulus Therapeutics Inc.